Enveric Biosciences (ENVB) Capital Expenditures (QoQ) (2016 - 2023)
Enveric Biosciences (ENVB) Capital Expenditures (QoQ) (2016 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -287.50% |
| Sep 30, 2023 | -55.56% |
| Jun 30, 2023 | -99.65% |
| Mar 31, 2023 | -16.53% |
| Dec 31, 2022 | -66.66% |
| Sep 30, 2022 | -65.53% |
| Jun 30, 2022 | -89.34% |
| Sep 30, 2020 | 281.12% |
| Jun 30, 2020 | -107.85% |
| Mar 31, 2020 | -23.41% |
| Jun 30, 2019 | 32.31% |
| Mar 31, 2019 | 166.31% |
| Dec 31, 2018 | -676.72% |
| Sep 30, 2018 | -116.68% |
| Dec 31, 2017 | -98,466.67% |
| Sep 30, 2017 | 99.89% |
| Jun 30, 2017 | -125.66% |
| Mar 31, 2017 | -99.68% |
| Dec 31, 2016 | 197.01% |
| Sep 30, 2016 | -285,904.30% |